Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal

Ambroise D Ahouidi; Mark Anderson; Cyrille K Diédhiou; Aminata Dia; Moustapha Mbow; Yacine Dia; Aminata Mboup; Astou Gueye Gaye; Noel M Manga; Gavin Cloherty; Souleymane Mboup

doi:10.1016/j.ijregi.2021.12.008

Seroprevalence of SARS-CoV-2 IgG antibodies in a healthcare setting during the first pandemic wave in Senegal

IJID Reg. 2022 Mar:2:96-98. doi: 10.1016/j.ijregi.2021.12.008. Epub 2021 Dec 24.

Affiliations

¹ Institut de Recherche en Sante, de Surveillance Epidemiologique Et de Formations, Arrodissement 4 Rue 2 D1, Pole Urbain de Diamiadio, BP 7325, Dakar, Senegal.
² Abbott Laboratories, Infectious Disease Research, Abbott Park, IL, USA.
³ Unit of Infectious and Tropical Diseases, Assane Seck University, Hospital de la Paix, Ziguinchor, Senegal.

Abstract

This study investigated the seroprevalence of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) immunoglobulin G (IgG) during the first pandemic wave in Senegal. The seroprevalence rate of SARS-CoV-2 IgG was assessed in 10 cities in Senegal by testing plasma from volunteers attending healthcare clinics for reasons unrelated to coronavirus disease 2019 (n=3231) between June and October 2020. The overall positivity rate was 20.4% and large geographical differences in seropositivity (6-41.9%) were observed, suggesting that the true number of infections was substantially higher than the official estimate of 8.5%.

Keywords: IgG; SARS-Cov-2; Senegal; Serosurvey; healthcare.

Grants and funding

U01 AI151698/AI/NIAID NIH HHS/United States